How to contribute

 ECCO Congress

The annual ECCO Congress offers a wide range of sponsorship option and provide flexible exhibition booths sizes. The booking process of the opportunities is supported by the ECCO Industry Webshop with the first release available usually in June. At that stage, the satellite symposia slots and exhibition booth booking are opened accompanied by other significant sponsorship items. The venue branding items, digital sponsorship options, and other possibilities are usually released in September.

In case you would like to be informed about the expected dates and the list of items before the release, please send an email to the Congress Team (This email address is being protected from spambots. You need JavaScript enabled to view it.) and you will be added to the mailing list.

---

Association Projects

Association initiatives provide opportunities based on following funding scheme:

Educational/Unrestricted Grants:

E-QUALITY: ECCO Quality of Care Project

The E-QUALITY project is a new initiative of the European Crohn’s and Colitis Organisation to ultimately improve the quality of care of patients living with Inflammatory Bowel Diseases (IBD). With this project, ECCO emphasizes its statutory mission: To improve the care of all patients with IBD in all its aspects through international guidelines for practice, education, research and collaboration in the area of IBD.

You can find further information here.

Sponsorship Live Events:

ECCO Educational Workshops

The primary goal of ECCO Educational Workshops is to harmonise IBD practices within ECCO Country Members by presenting the practical use of the ECCO Guidelines on Crohn's Disease and Ulcerative Colitis. Additionally, the Workshops provide continuous medical education with the ultimate aim of improving the quality of care for patients with IBD. ECCO Educational Workshops are aimed at individuals who are interested in IBD and provide an ideal opportunity to network whilst receiving an update on the latest ECCO Guidelines by top gastroenterologists in Europe.

You can find further information here.

IBD Nurse Education programme

ECCO believes it is essential to develop a comprehensive, practical education programme for IBD Nurses, which aims to increase the number of IBD Nurses and enhances their role. Various discussions led by and with ECCO nurses have confirmed this need. In line with these discussions ECCO has launched an IBD Nurse Education Programme.  The 2nd cycle of the programme took place in Hungary in 2022/2023. The 3rd cycle of the programme will take place in France in 2024/2025.

Y-ECCO Mentorship Forum

This stand-alone event is aimed at transferring career and scientific knowledge from senior experts to junior gastroenterologists within the field of IBD. The Y-ECCO Mentorship Forum is about questioning, challenging, guiding and encouraging young doctors to develop skills and take steps to become the professionals they want to be. In addition, this forum should enable the participants to network with their peers and senior KOLs for potential future scientific collaboration.

You can find further information here.

For further details related to the association projects/detailed brochure on life events, please feel free to get in touch with the Association Team at This email address is being protected from spambots. You need JavaScript enabled to view it..

The following technically necessary cookies are used on our website:

Name: 2149cc4e3c77a794bc409dd46054bcb3 (session cookie)
Domain: https://www.ecco-ibd.eu
Access for script: No / HTTP Only
Purpose: Multilingualism and login verification
Expiry date: session end
Location of the recipient: Austria

Name: cpnb_cookieSettings
Domain: https://www.ecco-ibd.eu
Access for script: Yes
Purpose: Stores the preferences of visitors selected in the cookie box.
Expiry date: 1 Year after last visit
Location of the recipient: Austria

Name: cookiesDirective
Domain: https://www.ecco-ibd.eu
Access for script: Yes
Purpose: after clicking “Accept” in the cookie banner Stores the preferences of visitors selected in the cookie box.
Expiry date: 1 Year after last visit
Location of the recipient: Austria

Name: cpnbCookiesDeclined
Domain: https://www.ecco-ibd.eu
Access for script: Yes
Purpose: after clicking “Decline” in the cookie banner stores the preferences of visitors selected in the cookie box.
Expiry date: 180 days after last visit
Location of the recipient: Austria

Name: __cf_bm (session cookie)
Domain: https://www.vimeo.com
Access for script: No / HTTP Only
Purpose: part of Cloudflare's Bot Management service and helps mitigate risk associated with spam and bot traffic
Expiry date: 24 hours after session end
Location of the recipient: Canada via Cloudflare, Inc.

Name: PHPSESSID (session cookie)
Domain: https://survey.ecco-ibd.eu
Access for script: No / HTTP Only
Purpose: User authentication
Expiry date: session end
Location of the recipient: Austria

Name: YII_CSRF_TOKEN (session cookie)
Domain: https://www.survey.ecco-ibd.eu
Access for script: No / HTTP Only
Purpose: User authentication
Expiry date: session end
Location of the recipient: Austria

Name: __RequestVerificationToken_ (session cookie)
Domain: https://cm.ecco-ibd.eu
Access for script: No / HTTP Only
Purpose: User authentication
Expiry date: session end
Location of the recipient: Austria

Name: ASP.NET_SessionId (session cookie)
Domain: https://cm.ecco-ibd.eu
Access for script: No / HTTP Only
Purpose: User authentication
Expiry date: session end
Location of the recipient: Austria

Name: .AspNet.AplicationCookie (session cookie)
Domain: https://cm.ecco-ibd.eu
Access for script: No / HTTP Only
Purpose: User authentication
Expiry date: session end
Location of the recipient: Austria

Name: cmooffice-aaas-isauthenticated (session cookie)
Domain: https://cm.ecco-ibd.eu
Access for script: No / HTTP Only
Purpose: User authentication
Expiry date: session end
Location of the recipient: Austria

Name: cmooffice-aaas-session (session cookie)
Domain: https://cm.ecco-ibd.eu
Access for script: No / HTTP Only
Purpose: User authentication
Expiry date: session end
Location of the recipient: Austria

Name: cmooffice-aaas-state (session cookie)
Domain: https://cm.ecco-ibd.eu
Access for script: No / HTTP Only
Purpose: User authentication
Expiry date: session end
Location of the recipient: Austria

Name: oc_sessionPassphrase (session cookie)
Domain: https://c1601.cloudbox.at
Access for script: No / HTTP Only
Purpose: User authentication
Expiry date: session end
Location of the recipient: Austria

Name: ocd7az2svarz (session cookie)
Domain: https://c1601.cloudbox.at
Access for script: No / HTTP Only
Purpose: User authentication
Expiry date: 24 hours after session end
Location of the recipient: Austria

Name: MoodleSession (session cookie)
Domain: https://e-learning.ecco-ibd.eu
Access for script: Yes
Purpose: User authentication
Expiry date: session end
Location of the recipient: Austria

Name: intro (session cookie)
Domain: https://www.e-guide.ecco-ibd.eu
Access for script: Yes
Purpose: User authentication
Expiry date: session end
Location of the recipient: Austria

Name: SESS (session cookie)
Domain: https://www.e-guide.ecco-ibd.eu
Access for script: No / HTTP Only
Purpose: User authentication
Expiry date: 24 days after session end
Location of the recipient: Austria

Name: SESS (session cookie)
Domain: https://www.e-guide.ecco-ibd.eu/
Access for script: No / HTTP Only
Purpose: User authentication
Expiry date: 24 days after session end
Location of the recipient: Austria

Name: wwhmid (session cookie)
Domain: https://www.hotelmap.com
Access for script: No / HTTP Only
Purpose: User authentication
Expiry date: 56 days after session end
Location of the recipient: Ireland via AWS EC2 (eu-west-1)

Name: 1bba2bdc05ab4257c3fe291f61a72270 (session cookie)
Domain: https://spo.ecco-ibd.eu
Access for script: No / HTTP Only
Purpose: Multilingualism and login verification
Expiry date: session end
Location of the recipient: Austria

Name: code_cmoffice (session cookie)
Domain: https://spo.ecco-ibd.eu
Access for script: Yes
Purpose: User authentication
Expiry date: session end
Location of the recipient: Austria

Name: joomla_user_state (session cookie)
Domain: https://spo.ecco-ibd.eu
Access for script: No / HTTP Only
Purpose: Login verification Joomla
Expiry date: session end
Location of the recipient: Austria

Name: rand (session cookie)
Domain: https://spo.ecco-ibd.eu
Access for script: Yes
Purpose: Login verification cmOffice
Expiry date: session end
Location of the recipient: Austria

Name: return (session cookie)
Domain: https://spo.ecco-ibd.eu
Access for script: Yes
Purpose: Login verification cmOffice
Expiry date: session end
Location of the recipient: Austria

Name: status (session cookie)
Domain: https://spo.ecco-ibd.eu
Access for script: Yes
Purpose: Login verification cmOffice
Expiry date: session end
Location of the recipient: Austria

Name: cart (session cookie)
Domain: https://spo.ecco-ibd.eu
Access for script: Yes
Purpose: Saves the user's shopping cart
Expiry date: 30 days after session end
Location of the recipient: Austria

Current JCC eTOC

Please find here the JCC eTOC service, the table of contents for each new issue that is always being updated. Don’t miss this excellent tool for keeping up-to-date on newly published articles.

Journal of Crohn's and Colitis Current Issue Correction to: Autoimmune Pancreatitis in Patients with Inflammatory Bowel Disease: A Real-World Multicentre Collaborative ECCO CONFER StudyMon, 19 May 2025 00:00:00 GMT by NIHR Oxford Biomedical Research Centre10.13039/501100013373Read more Correction to: Volume 18, Supplement 1Fri, 16 May 2025 00:00:00 GMT by This is a correction to Volume 18, Supplement 1, https://academic.oup.com/ecco-jcc/issue/18/Supplement_1Read more Correction to: Post-Discharge Outcomes of Elderly Patients Hospitalized for Inflammatory Bowel Disease Flare Complicated by Clostridioides difficile InfectionThu, 15 May 2025 00:00:00 GMT by This is a correction to: Idan Goren, Ortal Fallek Boldes, Tomer Boldes (et al), Post-Discharge Outcomes of Elderly Patients Hospitalized for Inflammatory Bowel Disease Flare Complicated by Clostridioides difficile Infection, Journal of Crohn’s and Colitis, 2024; https://doi.org/10.1093/ecco-jcc/jjae161Read more Be precise, be reproducible! The emerging role of artificial intelligence in inflammatory bowel disease endoscopyThu, 08 May 2025 00:00:00 GMT by Grading endoscopic disease activity is of pivotal importance in the management of patients with ulcerative colitis (UC) as patients achieving endoscopic healing have significantly more favorable clinical course, as exemplified by long-term steroid-free clinical remission and colectomy-free survival¹.Read more Early intestinal ultrasound response to biologic and small molecule therapy is accurate to predict treat-to-target endoscopic outcomes in children with ulcerative colitis: results from the prospective super sonic-UC studyFri, 02 May 2025 00:00:00 GMT by Read more Expert recommendations to standardize transcriptomic analysis in inflammatory bowel disease clinical trialsTue, 29 Apr 2025 00:00:00 GMT by

Abstract

Background and aims

Substantial methodological and reporting heterogeneity confounds the interpretation and generalizability of transcriptomic data for inflammatory bowel disease (IBD) studies. We aimed to develop recommendations to standardize transcriptomic research in clinical trials.

Methods

A 2-part study was undertaken. A systematic review identified reports of transcriptomic analyses utilizing samples from IBD clinical trials. Studies that used global RNA assay platforms were included. Data regarding study design, methodological approaches, and reporting of transcriptomic research were extracted. The systematic review results informed a modified Research and Development/University of California Los Angeles appropriateness methodology process and the development of survey statements focused on topics with substantial methodological heterogeneity. A panel of 16 IBD translational researchers and gastroenterologists rated the appropriateness of survey statements in 2 rounds.

Results

The systematic review identified 37 reports that included transcriptomic analyses of samples from IBD patients. The appropriateness of 416 statements was rated by 15 panellists in the first survey. The final survey included 305 statements, of which 14 panellists rated 75% appropriate, 1% inappropriate, and 24% uncertain. The panel determined that transcriptomic analysis for multiple research objectives was appropriate at most phases of clinical development in patients with active disease. Recommendations regarding study sample size; biopsy number, location, preservation, and storage; and data analysis and reporting were also generated.

Conclusion

The persistence of existing methodologic heterogeneity may continue to limit the value of transcriptomic research in IBD. This study provides expert recommendations to address and overcome these discrepancies and foster the inclusion of this research in clinical development.Read more Endoscopic submucosal dissection for visible dysplasia in inflammatory bowel disease: a nationwide multicenter cohort from the GETAID and the SFEDFri, 25 Apr 2025 00:00:00 GMT by Read more A multicenter study of the real-world effectiveness and safety of risankizumab in Crohn’s diseaseThu, 24 Apr 2025 00:00:00 GMT by Read more 5-Aminosalicylates for non-surgical patients with active or quiescent Crohn’s disease: an overview of systematic reviews (umbrella review)Mon, 21 Apr 2025 00:00:00 GMT by Read more Triple biologic therapy for refractory Crohn’s diseaseSat, 19 Apr 2025 00:00:00 GMT by

Abstract

Background

Despite significant advances in the therapeutic management of Crohn’s disease (CD), a subset of patients remains refractory to available treatments. Dual-targeted therapy (DTT), combining biologics or biologics with small molecules, has emerged as a promising approach. While evidence supporting DTT continues to grow, reports of patients treated with a combination of 3 biologic or targeted agents remain exceptionally rare.

Case Presentation

We report the case of a 30-year-old male with a complex clinical course, initially diagnosed with ulcerative colitis and later reclassified as CD following ileal pouch-anal anastomosis, due to subsequent small bowel and perianal involvement. The patient also had concomitant ankylosing spondylitis. Despite multiple lines of therapy, including, anti-tumor necrosis factor agents, vedolizumab, ustekinumab, and upadacitinib, both CD and ankylosing spondylitis remained clinically active. In the absence of alternative therapeutic options and continued refusal of surgery, a triple combination of certolizumab pegol, ustekinumab, and vedolizumab was initiated and maintained over 10 months. While the treatment was well tolerated and ankylosing spondylitis remained in remission, no impact was observed on CD.

Discussion

This case highlights the challenges of managing refractory inflammatory bowel disease with overlapping immune-mediated conditions. Although the combination of biologics targeting distinct inflammatory pathways is conceptually appealing and supported by emerging data on DTT, the effectiveness of triple therapy remains uncertain in some patients.

Conclusions

Triple biologic therapy remains experimental and should be approached with caution, pending more robust evidence. Larger and translational studies are needed to better identify patients who may benefit, define optimal combinations, and clarify long-term safety of these combinations.Read more Anti-integrin αvβ6 IgG antibody as a diagnostic and prognostic marker in ulcerative colitis: A cross-sectional and longitudinal study defining a specific disease phenotypeSat, 19 Apr 2025 00:00:00 GMT by Read more Biglycan deficiency alleviates intestinal fibrosis through BMP-7-mediated Smad1/5/8 signalingFri, 18 Apr 2025 00:00:00 GMT by Read more Drug tissue concentration and STAT3 modulation as determinants of tofacitinib response in ulcerative colitisThu, 17 Apr 2025 00:00:00 GMT by

Abstract

Introduction

Inflammatory bowel disease management has advanced with therapies like Janus kinase inhibitors (JAKi). Despite their promise, JAKi pharmacokinetic-pharmacodynamic (PK-PD) profiles and tissue-level effects remain underexplored. This study investigates tissue and serum tofacitinib levels, their correlation with therapeutic efficacy, and molecular mechanisms underlying treatment response.

Methods

Thirty refractory ulcerative colitis (UC) patients receiving tofacitinib were prospectively studied. Tissue biopsies and serum samples were collected pre- and post-induction for PK analysis using liquid chromatography mass spectrometry. RNA sequencing and cytokine profiling were performed on tissue samples to explore molecular responses. Endoscopic improvement was defined as a Mayo endoscopic subscore of 0-1 by week 16.

Results

Tofacitinib tissue concentrations were 25-fold higher than serum levels and significantly correlated (ρ=0.92, P < .001). Responders showed significantly higher tissue drug exposure (1047.5 ng/g vs 467.1 ng/g, P = .02) at the time of endoscopic assessment. Tofacitinib treatment reduced phosphorylated STAT3 (pSTAT3) levels, particularly in responders (P = .02). RNA sequencing revealed gene modules linked to tissue drug and pSTAT3 concentrations. Gene set enrichment analysis showed that these were more frequent in non-responders and associated with JAK-STAT pathways.

Conclusions

This study underscores the importance of tissue tofacitinib levels in UC treatment efficacy, with pSTAT3 reduction serving as a potential marker of drug efficacy. RNA sequencing identified molecular pathways for potential biomarkers and novel therapeutic targets in tofacitinib non-responders.Read more Effectiveness and safety of rectal tacrolimus in patients with ulcerative colitis. TACRO-TOPIC study of GETECCUThu, 10 Apr 2025 00:00:00 GMT by Read more Association of bile acid diarrhea with symptoms and disease activity in Crohn’s disease: post-hoc clinical trial analysis of serum 7a-hydroxy-4cholestern-3-one, C4, in patients with active Crohn’s diseaseWed, 09 Apr 2025 00:00:00 GMT by Read more The mediating role of psychological inflexibility on internalized stigma and patient outcomes in a sample of adults with inflammatory bowel diseaseTue, 01 Apr 2025 00:00:00 GMT by

Abstract

Background

This study examined the relationship between psychological inflexibility, internalized stigma, and patient outcomes in adults with inflammatory bowel disease (IBD). It aimed to explore if psychological inflexibility mediated the relationship between internalized stigma and patient outcomes.

Methods

Three hundred and eighty-two participants with IBD took part in a cross-sectional quantitative study conducted via an online survey from May to December 2020. Participants completed questionnaires that assessed psychological inflexibility, committed action, internalized stigma related to IBD, psychological distress, IBD self-efficacy, self-concealment, beliefs about emotions, and fatigue. Participants also completed a sociodemographic and clinical questionnaire in addition to a bespoke Covid-19 questionnaire. Pearson’s correlations and exploratory simple mediation analyses were used to examine relationships between variables and the mediating effect of psychological inflexibility.

Results

40.5% of participants experienced internalized stigma. Higher psychological inflexibility was associated with higher internalized stigma, lower committed action, poorer health-related quality of life, lower IBD self-efficacy, higher self-concealment, higher fatigue, and more negative beliefs about emotions. Psychological inflexibility partially mediated the relationship between internalized stigma and several patient outcomes (psychological distress, IBD health-related quality of life, IBD self-efficacy, and self-concealment) and completely mediated the relationship between internalized stigma and fatigue.

Conclusion

Psychological inflexibility significantly impacts the quality of life in individuals with internalized stigma related to IBD and mediates the relationship between internalized stigma and patient outcomes. Increasing psychological flexibility in adults with IBD may reduce distress and enhance quality of life. Longitudinal studies and trials of psychological interventions targeting psychological flexibility warrant exploration.Read more Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort studyTue, 01 Apr 2025 00:00:00 GMT by

Abstract

Background and aims

Inflammatory bowel disease (IBD) patients with Clostridioides difficile infection (CDI) are at increased risk of adverse outcomes. Data on fidaxomicin use in IBD remain scarce. We assessed the effectiveness and safety of fidaxomicin for CDI and its impact on IBD outcomes in a large international cohort.

Methods

Adult patients with ulcerative colitis (UC) or Crohn’s disease (CD) treated with fidaxomicin for documented CDI were retrospectively included. The primary outcome was CDI recurrence rate within 8 weeks (C. difficile toxin detection and CDI-targeted therapy). Secondary outcomes included sustained response (no CDI-targeted therapy within 12 weeks), IBD therapy escalation, colectomy rate, and all-cause mortality within 30, 90, and 180 days.

Results

Ninety-six patients (57 UC and 39 CD) from 20 IBD centers were included. Most were on advanced IBD therapy. Half had a previous CDI episode, 15% a severe episode. CDI recurrence rate was 10% at week 8, and sustained response 82% at week 12. Compared with patients with previous CDI episode, patients at first episode tended to have a lower recurrence (4.3% vs 16%; P = .06) and higher sustained response (91% vs 75%; P = .04) rate. IBD therapy escalation was required in 48% with a numerically lower need for patients achieving vs not-achieving sustained response within 30 days (12% vs 20%; P = .42). Five UC patients underwent colectomy. One death unrelated to CDI or IBD occurred. One moderate and 5 mild adverse events were reported.

Conclusions

Fidaxomicin was effective and safe in IBD patients with CDI, with greater effectiveness in CDI-naïve patients, potentially influencing short-term IBD outcomes.Read more Real-world effectiveness of ustekinumab versus anti-TNF or vedolizumab in ulcerative colitis: induction and 12-month maintenance results from the prospective, observational RUN-UC studyThu, 27 Mar 2025 00:00:00 GMT by

Abstract

Background

Real-world evidence studies of ustekinumab (UST) in ulcerative colitis (UC) are needed because randomized controlled trials do not represent unselected patient populations in everyday clinical practice. Patients with UC were recruited when starting biologic therapy for the first time or switching to a new biologic therapy. This study assessed the effectiveness of maintenance therapy with UST in comparison to anti-TNF or vedolizumab (VDZ) at 12 months.

Methods

Between 2020 and 2022, 507 UC patients starting biologic therapy for the first time or switching to a new biologic therapy were enrolled at 34 inflammatory bowel disease (IBD)-specialized centers in Germany. After excluding patients receiving other biologics or small molecules, as well as those with stomas or missing outcomes, the final sample consisted of 476 patients. The outcomes were clinical response, clinical remission (CR), and steroid-free remission. Propensity score (PS) adjustment with inverse probability of treatment weighting was used to reduce the effect of confounding due to physician selection of therapy.

Results

A total of 476 patients with UC were included in the analysis (UST: 147, anti-TNF: 168, VDZ: 161). Treatment persistence over 12 months differed significantly (P < .001) between UST (93.9%), VDZ (87.0%), and anti-TNF (75.0%). The PS-weighted effectiveness of UST in the mITT analysis at month 12 was not significantly different from anti-TNF or VDZ (CR: UST 26.9%, anti-TNF 34.7%, VDZ 40.9%; P = .063).

Conclusions

In the prospective RUN-UC study with PS-weighted groups, UST showed higher treatment persistence but no significant difference in maintenance effectiveness compared to anti-TNF or VDZ in UC.Read more The use of International Bowel Ultrasound Segmental Activity Score (IBUS-SAS) in patients with ulcerative colitis: applicability and comparison with other ultrasound scoresMon, 24 Mar 2025 00:00:00 GMT by

Abstract

Background and aims

The International Bowel Ultrasound Segmental Activity Score (IBUS-SAS) is an intestinal ultrasound (IUS) score validated for Crohn’s disease, potentially applicable to ulcerative colitis (UC). We aimed to confirm the applicability of IBUS-SAS to UC, while comparing its performance with other IUS scores.

Methods

Adult patients with UC undergoing colonoscopy were prospectively included and scored with both the Mayo Endoscopic Subscore (MES) and the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Intestinal ultrasound was performed within 4 weeks of endoscopy, measuring IBUS-SAS and other 5 UC-developed IUS scores. The Spearman’s rank coefficient (ρ) was used to perform correlations, while receiver operating characteristic curves were compared with the Hanley & McNeil method.

Results

In total, 185 patients were included. The IBUS-SAS showed a strong correlation with both the MES (ρ = .72, P < .01) and the UCEIS (ρ = .73, P < .01). Its area under the curve to detect an endoscopic activity of at least moderate severity (MES ≥ 2 and UCEIS ≥ 5) was 0.87 and 0.89, respectively. The optimal cutoffs of IBUS-SAS to detect a MES ≥ 2 and an UCEIS ≥ 5 were > 19 (sensitivity 79%, specificity 84%) and > 23 (sensitivity 88%, specificity 75%), respectively. Consistently, all the investigated IUS scores correlated with both the MES and the UCEIS (P < .01).

Conclusions

The IBUS-SAS has an optimal performance in the assessment of UC endoscopic activity, despite having been initially developed for CD. Therefore, it might be adopted as a reference score both for CD and UC activity.Read more Characterization of Inflammatory Bowel Disease Heterogeneity Using Serum Proteomics: A Multicenter StudyMon, 04 Nov 2024 00:00:00 GMT by

Abstract

Background

Recent genetic and transcriptomic data highlight the need for improved molecular characterization of inflammatory bowel disease (IBD). Proteomics may advance the delineation of IBD phenotypes since it accounts for post-transcriptional modifications.

Aims

We aimed to assess the IBD spectrum based on inflammatory serum proteins and identify discriminative patterns of underlying biological subtypes across multiple European cohorts.

Methods

Using proximity extension methodology, we measured 86 inflammation-related serum proteins in 1551 IBD patients and 312 healthy controls (HC). We screened for proteins exhibiting significantly different levels among IBD subtypes and between IBD and HC. Classification models for differentiating between Crohn’s disease (CD) and ulcerative colitis (UC) were employed to explore the IBD spectrum based on estimated probability scores.

Results

Levels of multiple proteins, such as interleukin-17A, matrix metalloproteinase-10, and fibroblast growth factor-19, differed (fold-change >1.2; false discovery rate <0.05) between ileal versus colonic IBD. Using multivariable models, a protein signature reflecting the IBD spectrum was identified, positioning colonic CD between UC and ileal CD, which were at opposite ends of the spectrum. Based on area under the curve (AUC) estimates, classification models more accurately differentiated UC from ileal CD (median AUCs > 0.73) than colonic CD (median AUCs < 0.62). Models differentiating colonic CD from ileal CD demonstrated intermediate performance (median AUCs: 0.67–0.69).

Conclusions

Our findings in serum proteins support the presence of a continuous IBD spectrum rather than a clear separation of CD and UC. Within the spectrum, disease location may reflect a more similar disease than CD versus UC, as colonic CD resembled UC more closely than ileal CD.Read more Post-Discharge Outcomes of Elderly Patients Hospitalized for Inflammatory Bowel Disease Flare Complicated by Clostridioides difficile InfectionMon, 21 Oct 2024 00:00:00 GMT by Read more

 

Icons

Using: <span class="uk-icon-cog"></span>

• adjust
• anchor
• archive
• area-chart
• arrows
• arrows-h
• arrows-v
• asterisk
• at
• automobile (alias)
• balance-scale
• ban
• bank (alias)
• bar-chart
• bar-chart-o (alias)
• barcode
• bars
• battery-empty (alias)
• battery-0
• battery-quarter (alias)
• battery-1
• battery-half (alias)
• battery-2
• battery-three-quarters (alias)
• battery-3
• battery-full (alias)
• battery-4
• bed
• beer
• bell
• bell-o
• bell-slash
• bell-slash-o
• bicycle
• binoculars
• birthday-cake
• bluetooth
• bluetooth-b
• bolt
• bomb
• book
• bookmark
• bookmark-o
• briefcase
• bug
• building
• building-o
• bullhorn
• bullseye
• bus
• cab (alias)
• calculator
• calendar
• calendar-check-o
• calendar-minus-o
• calendar-o
• calendar-plus-o
• calendar-times-o
• camera
• camera-retro
• car
• caret-square-o-down
• caret-square-o-left
• caret-square-o-right
• caret-square-o-up
• cart-arrow-down
• cart-plus

More Icons: https://getuikit.com/v2/docs/icon.html

Buttons

For a short button: <a href="#" class="uk-button uk-icon-pdf">Text</a>

For a long button: <a href="#" class="uk-button uk-button-break uk-icon-pdf">Text</a>

uk-icon-pdf

uk-icon-at

uk-icon-calendar-plus

uk-icon-calendar-check

uk-icon-cloud-download

uk-icon-cloud-upload

uk-icon-external-link

uk-icon-file-audio

uk-icon-file-excel

uk-icon-file-image

uk-icon-file-powerpoint

uk-icon-file-word

uk-icon-file-video

uk-icon-film

uk-icon-file-zip

uk-icon-folder

uk-icon-folder-open

uk-icon-envelope

uk-icon-send

uk-icon-money

uk-icon-film

uk-icon-credit-card

uk-icon-eur

ECCO IT HUB (= ECCO DATABASE) –  PRIVACY POLICY ACCORDING TO GDPR

ECCO IT HUB consists of the following organisational entities with their registered seat in 1030 Wien, Ungargasse 6/13, and is based on a joint controllership agreement according to Article 26 General Data Protection Regulation (“GDPR”):

• ECCO – European Crohn’s and Colitis Organisation (“ECCO”), registered in the Austrian Register of Associations (ZVR) under the registration number 468755685, as well as its daughter entity:
• OCEAiN – Organisation, Congress, Emotion, Association, iNnovation GmbH (“OCEAiN”)

(together hereafter referred to as “ECCO IT HUB” or “we”).

1. Purpose

ECCO IT HUB solely processes your personal data for the purpose of:

• centralised and up-to-date data administration of ECCO Membership, Congress and event participations as well as stakeholder status in order to avoid scattering loss of up-to-date contact details among the business units of the joint data controllers

• ECCO Membership administration
• ECCO Congress abstract submission system
• ECCO Congress delegate registration
• ECCO Congress faculty registration
• ECCO Congress industry webshop and sponsor & exhibitor administration
• ECCO Virtual Congress – access administration
• ECCO Congress CME accreditation and administration
• ECCO e-Learning access administration
• ECCO Educational Workshop registration
• ECCO supplier and employee contact administration

• facilitating communication among stakeholders of the IBD Community (= the data subjects in the ECCO Database) and making relevant data visible via the ECCO Website and the ECCO App (including the display of names and affiliations of Congress speaker and ECCO Officer and the disclosure of conflicts of interest, names and affiliation)
• Promotion of ECCO Congress and Association activities
• ECCO Congress programme publication
• ECCO Congress abstract publication
• ECCO Virtual Congress platform
• ECCO Congress onsite speaker centre
• ECCO Disclosure policy of potential conflicts of interest
• ECCO Organs communication & meeting organisation
• ECCO General Assembly voting administration
• ECCO Manuscript development (Guidelines, Topical Reviews, Scientific Workshop Papers, Position Statements)
• ECCO e-Learning content development
• ECCO e-Guide content development
• Publication of ECCO News
• ECCO Website security measures and fraud prevention
• the collection and selection process with respect to open research calls, open manuscript-project calls and open calls for positions in ECCO
• Nomination collection for IBD Intensive Course for Trainees and N-ECCO School held at the annual ECCO Congress
• ECCO Organs elections - application collection
• ECCO Fellowships and Grants - application collection
• ECCO Manuscript- application collection (Guidelines, Topical Reviews, Scientific Workshop Papers, Position Statements)
• ECCO CONFER project case proposal collection
• facilitating the whole process of submission, review and publication of scientific abstracts of the annual ECCO Congress as well as facilitating the scientific review of ECCO Fellowships and Grants application
  • ECCO Congress Abstracts – scientific review
  • ECCO Fellowships and Grants – scientific review
• conducting statistical analyses and reports
• ECCO Congress, Membership and project statistics
• ECCO Website statistics for internal market research purposes
• ECCO App statistics
• ECCO Congress industry badge scanners

2. Legal basis of data collection

ECCO IT Hub only processes your personal data as follows:

• We will ask your consent to process your data in the following areas of our Website/App. You may withdraw your consent at any time. The withdrawal of your consent shall not affect the lawfulness of processing based on consent before its withdrawal:
  • ECCO Website cookies
  • ECCO Portal Account set-up
  • ECCO App installation and usage
  • ECCO e-Learning access for non-member health-care professionals until the age of 35
  • ECCO eNewsletter subscription of ECCO Portal Account Holders (without Membership)
  • Replies to open calls of ECCO (ECCO Organs, Manuscripts, Fellowships and Grants, IBD Intensive Course for Trainees, N-ECCO School, CONFER project)
  • ECCO Educational Workshop registration
  • ECCO Congress Abstract submission
  • ECCO Scientific Reviewer status
  • ECCO Congress Faculty invitations (with a separate publication consent for congress material and, for poster presentations, the consent to be contacted by delegates with regards to their poster)
  • Personal contributions to ECCO Virtual Congress
  • Publication of personal disclosure information of potential conflicts of interest, of e-Learning and e-Guide material, of ECCO manuscripts and ECCO News

 

• in performance of our (pre-)contractual obligation
  • ECCO Congress registration
  • ECCO Congress exhibition and sponsorship
  • ECCO supplier and employee contact administration

 

• on legitimate interest according to of Article 6 of the GDPR:
  • ECCO Membership administration for the fulfilment of our association purpose.

 

• Photo policy:
  • Portrait pictures are submitted by data subjects themselves or taken by the ECCO photographer are based on your explicit consent, which can be withdrawn according to point 7 below.
  • As event organisers, ECCO and OCEAiN reserve the right on their legitimate interest to use ECCO Congress photos and film footage of the official ECCO photographers and film team (as also stated in the ECCO Congress registration terms and conditions) as well as to use photos of other ECCO events in which you might be captured.

Should you have a strong objection about a specific item, you can still address ECCO Office as outlined in point 7 below.

These photos and film footage are intended for reporting about the event on the ECCO Website, in the ECCO eNewsletters, in promotional material (such as Congress break slide) and in printing material (such as the ECCO Anniversary Book series). 

3. Data categories: What kind of data?

Your personal data will not be subject to further processing in a way and manner that are incompatible with the intended purposes listed above.

ECCO Website

ECCO IT Hub processes the IP address of ECCO Website visitors and cookie information chosen by you and as explained in the cookies setting banner:

• The IP address is transmitted with every server request. ECCO IT Hub and its provider of statistical services do not store IP addresses permanently, but use them for session identification purposes and to prevent attacks only. The following information will be stored in the server logs: the IP address of the requesting computer, together with the date, time, which file is requested (name and URL), what amount of data is transferred to you, a message as to whether the request was successful, identification data of the browser used and the operating system used, as well as the website from which access was made (if access is via a link).

 

• The ECCO Website uses Matomo Analytics software, which relies on cookies as well. They are stored on your computer and generate information for the analysis of the ECCO webpages used by you (including your IP address in anonymised form), which is stored on a server located in Austria.

 

• During your visit to the ECCO Website, some information is collected and analysed for web controlling purposes. This information is provided by your browser. The following data are collected:
  • Requests (file name of the requested file) (e.g., beispiel.de/index.html)
  • Browser type/browser version (e.g., Internet Explorer 6.0)
  • Browser language (e.g., English)
  • Operating system used (e.g., Windows XP)
  • Inner resolution of browser window
  • Screen resolution
  • JavaScript activation
  • Java on /off
  • Cookies on / off
  • Colour depth
  • Referrer URL (the previously visited web site)
  • Time of access
  • Clicks
  • Total orders, if any
  • Content of forms, if any (in the case of text fields, e.g. name and password, only the information “completed“ or “not completed“ is transmitted)
  • The ECCO Website relies on several so-called cookies, which are small text files that are placed on your computer and saved by your browser ( - access all cookie details under the cookie banner). Cookies cannot be used to identify specific individuals and do not contain personal data. Most of the cookies used are so-called “session cookies” that are deleted at the end of your browser session. In addition, there are some persistent cookies used to recognize you as a returning visitor to the website.

 

ECCO Portal Account Holders in ECCO IT Hub

ECCO IT Hub processes the following personal data as provided by you in setting up an ECCO Portal Account and choosing to participate in further interactions:

• name,
• email
• addresse(s)
• phone number(s)
• postal addresse(s)
• fax
• gender
• date of birth
• age
• profession
• professional specialization
• expertise & particular areas of interest
• HCP (health care professional) status,
• your ECCO Membership status (which may also be published once per year with names per country in the context of the ECCO Congress),
• applications to open calls, event and project participation(s)
• disclosures of potential conflicts of interest,
• reimbursement data,
• portrait pictures and event photos and film footage
• passport details for congress invitation letters.
• In addition, the scientific review process generates a review result for the submitters of abstracts and applications for fellowships and grants which will be stored in connection with the abstract submitted via the submitter’s account.
• The election process generates a ranking result which is kept confidential within ECCO Office archives.

If you participate in the ECCO App and/or an ECCO virtual event, you can choose to share your personal information as well as your opinion in public debates with the other participants.

• The content of all postings and the contribution to public debates is solely your responsibility as participant who chose to actively share information. Neither ECCO or OCEAiN nor their expert volunteers or staff members can be held liable for this posted content, while ECCO and OCEAiN reserve the right to edit, rectify or delete postings of participants for good faith or legal reason.
  • Self-management of consent-based data of ECCO Portal Account used for single-sign on solution in ECCO App: your first name, last name, and email address (= you can reject that the ECCO Portal data is shared with the ECCO App)
  • Self-management of data storage and data subject rights (= the users can delete themselves): social media, website, address, job title, biography, company, country, topics of interest, portrait picture, written chat contributions
  • No data storage; self-management of data subject rights in live engagement (= you can decide themselves when to turn on/off the camera/mic/screen sharing): camera image, audio transmission, image and screen sharing
  • While text postings on the social wall can be deleted by you on your own (= self-management of data subject rights) and with this deletion also the answer comments, you cannot delete on your own your answer-comments to postings.

You may withdraw your consent regarding consent based data at any time. The withdrawal of your consent shall not affect the lawfulness of processing based on consent before its withdrawal.

4. Data received from third parties (Article 14 of the GDPR)

Please note that in the context of the following group registration, nomination and submission processes, ECCO IT HUB received your personal data via the contact person of the respective group registration:

• Membership Group Registrations
  • Source of the data: tour operator agencies booking group memberships
  • Purpose: invitation to pre-paid ECCO Membership
  • Legal Basis: consent of data subject to tour operator agencies booking group registrations; these tour operators are under a contractual obligation with ECCO to collect your consent for this registration in advance.
  • Data categories processed: last name, email address and country

 

• Congress Group Registrations
  • Source of the data: tour operator agencies booking group registrations
  • Purpose: invitation to pre-paid ECCO Congress Registration
  • Legal Basis: consent of data subject to tour operator agencies booking group registrations; these tour operators are under a contractual obligation with OCEAiN to collect your consent for this registration in advance.
  • Data categories processed: last name, email address and country, badge-pick-up and certificates of attendances of their invited delegates in tour operator profile

 

• Nomination process of the candidates for the IBD Intensive Course for Trainees
  • Source of the data: National Representatives of ECCO Country Members
  • Purpose: invitation to free-of-charge educational course at ECCO Congress
  • Legal Basis: consent of data subject to respective ECCO National Representative submitting nominations for this course; legitimate interest of data subject to be admitted to this selective course.
  • Data categories processed: first name, last name, email address, city, country, years of experience, letter of intent

 

• Nomination process of candidates for the N-ECCO School
  • Source of the data: N-ECCO National Representatives of ECCO Country Members
  • Purpose: invitation to free-of-charge educational course at ECCO Congress
  • Legal Basis: consent of data subject to respective ECCO National Representative submitting nominations for this course; legitimate interest of data subject to be admitted to this selective course.
  • Data categories processed: first name, last name, email address, city, country, phone number

 

• Congress Abstract submission process for an author group
  • Source of the data: Abstract submitter
  • Purpose: participation in the abstract selection for Abstract presentations at the ECCO Congress
  • Legal Basis: consent of data subject to submitting author of the author group; legitimate interest of data subject to participate in this scientific abstract selection.
  • Data categories processed: first name, last name, email address, institute, department, city, country, conflicts of interest

Please note that data subjects of such group registrations are contacted by ECCO Office within the first month with full transparency about this general ECCO Privacy Policy outlined here. 

As a data subject, you can address the contact point and data protection officers indicated above as well as the data protection authority indicated below.

5. Data recipients and sub-processors:

• European recipients and sub-processors:

In order to adequately fulfil the intended purposes listed above, ECCO IT Hub contracts primarily data processors based in the European Union – including but not limited to:

• COVR / Netropolix : https://www.netropolix.be/ for the customer management system of the ECCO Database
• SOL4: https://www.sol4.at/ for ECCO Website Support
• Conference Compass: https://www.conferencecompass.com/ for the ECCO App software
• Rapidmail: rapidmail.de for ECCO eNewsletter distribution,
• Viveum: www.viveum.com  as ePayment system on the ECCO Website
• GTN: https://gtn-solutions.com/ as e-Learning platform support

 

In the group registration processes, group leaders have a restricted duplicate-check option via entering the correct email address and name.

• Non-European recipients and sub-processors:

 

• In case applications are submitted to the scientific review in the context of Fellowships and Grants application reviews and the Congress Abstract reviews, this process includes individual experts from outside of Europe.

 

• In case that Educational Workshops take place outside of Europe, the registration lists for this respective Workshop are shared with the local organiser.

 

• The ECCO Virtual Congress and event platform relies on some US-based IT Services such as the Vimeo video player and the Zoom online conference platform as well as on European IT Services with US-based sub-processors such as chat tools (incl. Slido: https://www.sli.do/ and Conference Compass: https://www.conferencecompass.com/  ) and networking tools. Online educational events will rely on a selection of these services as well.

 

• The ECCO Virtual Congress platform - and the online exhibition in particular - also features links to external company websites and chat tools – which are declared as such. This privacy policy and the terms and conditions of the ECCO Virtual Congress do not apply to these external websites, which need to be consulted separately for cookie and data protection policies. These websites are not within the responsibility of ECCO and OCEAiN, who may therefore not be held liable.

 

In case you explicitly consent to badge scanning in the ECCO Congress exhibition or satellite symposia, we transfer your personal data (Name; Contact details) to the exhibition or sponsor companies of the congress, some of which do have their head-quarters in the USA.  The current list of exhibitors can be found on the annual Congress Website (accessible via https://www.ecco-ibd.eu/congresses-and-events.html )  in the exhibitor section. You may withdraw your consent at any time. The withdrawal of your consent shall not affect the lawfulness of processing based on consent before its withdrawal.

6. Data storage time-frame:

ECCO IT Hub of course also observes the principle of storage limitation for personal data.

• IP address of ECCO Website visitors: The server logs are saved in order to be able to check the system security, to administrate the website technically and to be able to optimize the offer. The server logs are stored for the duration of 3 months. After this period the identity of the user can no longer be determined, even by ISPs.
• Anonymised IP address storage in the Matomo Analytics software of the ECCO Website: 24 months
• ECCO IT Hub will process the following data of Portal Account Holders until withdrawal of consent, but not longer than for 7 years:
  • name,
  • email
  • addresse(s)
  • phone number(s)
  • postal addresse(s)
  • fax
  • gender
  • date of birth
  • age
  • profession
  • professional specialization
  • expertise & particular areas of interest
  • HCP (health care professional) status,
  • your ECCO Membership status (which may also be published once per year with names per country in the context of the ECCO Congress),
  • applications to open calls, event and project participation(s)
  • disclosures of potential conflicts of interest,
  • reimbursement data
  • passport details for congress invitation letters.
  • In addition, the scientific review process generates a review result for the submitters of abstracts and applications for fellowships and grants which will be stored in connection with the abstract submitted via the submitter’s account.
  • The election process generates a ranking result which is kept confidential within ECCO Office archives.

• Beyond that time, ECCO IT Hub will only process your data (including photographs and video material) for association archive purposes, or if we are obliged to process your personal data by law.

Personal (non-scientific) supporting documents (such as letters of intent, CVs, publication lists), submitted in the context of applications to open calls, event and project participation(s)are stored not longer than 3 years.

7. Your rights as data subject:

Should you be affected by our processing of personal data, you have the right at any time to request access to, rectification, or erasure of personal data, or restriction of the processing concerning your personal data or to object to processing as well as the right to data portability.

As data subject, you may withdraw your consent for

• ECCO Website cookies (via deinstallation on user side)
• ECCO Portal Account set-up
• ECCO App installation and usage (via deinstallation on user side)
• ECCO e-Learning access for non-member health-care professionals until the age of 35
• ECCO eNewsletter subscription of ECCO Portal Account Holders (without Membership)
• Replies to open calls of ECCO (ECCO Organs, Manuscripts, Fellowships and Grants, IBD Intensive Course for Trainees, N-ECCO School, CONFER project)
• ECCO Educational Workshop registration
• ECCO Congress Abstract submission
• ECCO Scientific Reviewer status
• ECCO Congress Faculty invitations (with a separate publication consent for congress material)
• Personal contributions to ECCO Virtual Congress
• Publication of personal disclosure information of potential conflicts of interest, of e-Learning and e-Guide material, of ECCO manuscripts and ECCO News
• ECCO Congress – Industry Badge Scanner consent
• Portrait pictures (and event photos and film footage)

from ECCO IT HUB to process your personal data at any time under This email address is being protected from spambots. You need JavaScript enabled to view it. or This email address is being protected from spambots. You need JavaScript enabled to view it. or by postal mail to ECCO Office, Ungargasse 6/13, A-1030 Vienna, Austria.

Please note that the withdrawal of your consent shall not affect the lawfulness of processing based on consent before its withdrawal, and that in certain circumstances ECCO IT Hub is entitled or else required to process certain forms of personal data for a period extending beyond the withdrawal of consent, either due to our contractual relationship with you, or else due to legal requirements.

According to Art. 13 (2) e GDPR, you are not obliged to agree to the processing of your data. However, please also note

• that in case of the withdrawal of consent you will not be able to benefit or use all functions of ECCO IT Hub;
• that in case of disagreement with the processing of necessary data for (pre-) contractual obligations, the business transaction cannot be implemented;
• that in case you disagree with the legitimate interest according to of Article 6 of the GDPR regarding ECCO Membership, you will not be able to become an ECCO Member.

You directly access and modify your information via your personal log-in under the following link: https://cm.ecco-ibd.eu/cmgateway/member/NW/index.html?module=relationmanager&config=normal#manageprofiles.

In case you believe that the processing of your personal data does not comply with the provisions of data protection, you can – other legal remedies in law courts or under administrative law notwithstanding – make a complaint with a supervisory authority, in particular in the Member State of your habitual residence, place of work or place of the alleged infringement. In Austria, the supervisory authority is the Austrian Data Protection Authority (Österreichische Datenschutzbehörde).

According to Art. 13 (2) f GDPR, ECCO IT HUB does not generate automatic decisions including data profiling.

8. Nature of joint data processing by ECCO and OCEAiN:

The essence of the ECCO IT Hub arrangement according to Article 26 GDPR:

(Updated with JCA revised text per March 15, 2020)

DESCRIPTION OF JOINT DATA PROCESSING OPERATIONS:

The ECCO Database constitutes the core for all projects on the side of ECCO Association as well the side of OCEAiN GmbH, who is in charge of organising the annual ECCO Congress, the e-Learning platform and publishing the ECCO News magazine.

As the ECCO Congress constitutes the annual meeting of the ECCO Members and other stakeholders in the field of inflammatory bowel diseases, the ECCO Database has a significant intersection set of data subjects as the same data subjects can be ECCO Members and Congress Delegates. 

The data subjects in the ECCO Database are health care professionals, pharma industry representatives, patient representatives and students in the field of inflammatory bowel diseases with an interest in both ECCO Association activities and ECCO Congress and e-Learning activities. In addition, the ECCO Database captures press contacts, as well as employees and contact persons of tour operator agencies booking group registrations and of supplier companies, which are contracted to implement projects of ECCO and OCEAiN. 

MEANS OF JOINT DATA PROCESSING OPERATIONS: 

With the increasingly enhanced digitalisation of the joint data processing operations over the past years, the ECCO Website with a Login-Area called the ECCO Portal constitutes the main entrance door to all activities of ECCO and OCEAiN.

The ECCO Portal Account is the “front” side entrance door to and, after personal Login-In, the front side display of the respective personal data-set captured in the ECCO Database.

As soon as an ECCO Portal Account holder applies for ECCO Membership or engages in another activity, joint processing takes place in the ECCO Database: the use of synergy effects in data harmonization also aims to facilitate access of  data subjects to activities within the larger framework of ECCO IT Hub (e.g. distribution of our newsletters, promotion of our Congress and educational/scientific activities, access facilitation via the publisher/distributor of our publications). 

Depending on the status of the data subject (e.g.: Membership status, Congress Registration statutes, Scientific Reviewer Status), the data subject can access various online tools (e.g.: online application process per open call, registration process for workshops or ECCO Congress, industry webshop)  and various levels of online content (e.g.: applications received for internal or scientific review, e-Learning material, meeting documents).

Most of the functionalities are directly provided by the ECCO Database suppliers and do not need data transfers to other suppliers.

The ECCO Website and the ECCO Database are hosted on a rented ECCO Server space in Austria.

Additional Platforms and technology needed are solved with a single-sign on technology with the ECCO Database, which are in particular

• the ePayment tool used to process online credit card payments for ECCO Membership and ECCO Congress Registrations.
• the e-Learning platform which is accessible to all ECCO Members and also to health care professionals as ECCO Portal Account holders without active ECCO Membership up to the age of 35. The single-sign on mechanism is based on an age check, which takes place within the ECCO Database before the access interface is enabled to the e-Learning Platform.
• the ECCO App: upon installation of the ECCO App (offering a dedicated section for ECCO Association and another dedicated section for the annual Congress) on the data subject’s mobile device, first name, last name and email address is shared with the App provider company to allow the single-sign-on mechanism. In case of additional consent of the data subject chosen in  the settings of the App, the personal status (of Membership or Congress Delegates) can be shared in order to be visible for a chat-function tool.

 

In addition, two further joint data processing platforms are used to facilitate project management and communication:

• the ECCO Office inhouse server
• the eNewsletter Mailing Platform

PURPOSE OF JOINT DATA PROCESSING OPERATIONS: please refer to point 1 above.

CATEGORIES OF DATA PROCESSED UNDER THIS AGREEMENT: please refer to point 3 above.

DATA STORAGE LIMITATION: please refer to point 6 above.

ALLOCATION OF DATA PROTECTION TASKS/DUTIES (under Art. 26 GDPR)

The data protection tasks done jointly are

• provision of information according to Article 26 paragraph 2 sentence 2 GDPR
• common contact point for the fulfilment of data subjects’ requests,
• information obligation according to Article 13 / 14 GDPR,
• fulfilment of the request of access,
• fulfilment of the request of rectification,
• fulfilment of the request of erasure and restriction of processing,
• notification to recipients (Article 19 GDPR),
• fulfilment of the request of data portability, processing of withdrawals,
• implementation of technical and organisational measures (Article 32 GDPR),
• review and adaption of technical and organisational measures,
• maintenance of a record of processing activities

 

The data protection tasks done separately are:

• selection and assignment of data processors
• processing of notifiable data breaches

 

CONTACT POINT ACCORDING TO ARTICLE 13, 14 and 26 GDPR:

ECCO Office
Ungargasse 6/13, A-1030 Vienna, Austria.
Tel: +43-(0)1-710 2242-0
Fax: +43-(0)1-710 2242-001

E-Mail: This email address is being protected from spambots. You need JavaScript enabled to view it. or This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Data ProTection Officer ACCORDING TO ARTICLE 37 GDPR:

Knyrim Trieb Rechtsanwälte OG

Mariahilfer Straße 89a, A-1060 Wien

T: +43 1 909 30 70, F: +43 1 9093639

E: This email address is being protected from spambots. You need JavaScript enabled to view it., W: www.kt.at

FN 462250f, HG Wien